Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- correlation of microbiome composition or serum metabolomics with pain reduction
研究概览
简要总结
Fibromyalgia is a chronic condition that causes widespread pain, fatigue, and other symptoms, significantly affecting quality of life. Unfortunately, there are few effective treatments available. Recently, medical cannabis has gained attention as a potential treatment, leading many countries to approve its use for fibromyalgia. However, its success is limited-only about 25% of patients experience meaningful pain relief, and side effects like dizziness or fatigue are common. Not everyone responds to medical cannabis the same way, and researchers think this variability may partly be explained by differences in the gut microbiome-the community of bacteria and other microorganisms living in our digestive system. These microbes are known to influence various aspects of health, including pain and how the body processes medications. Our research focuses on understanding the link between the gut microbiome and fibromyalgia. We propose a study where 150 fibromyalgia patients will be treated with either cannabis oil or a placebo in a double-blind trial. By analyzing their symptoms and gut microbiome, we hope to identify patterns that could predict who will benefit most from cannabis treatment. If successful, this research could lead to more personalized and effective treatment options for fibromyalgia.
详细描述
This study aims to explore the potential association between the composition of the gut microbiome and the individual response to cannabis oil in individuals with fibromyalgia. We propose a double-blinded randomized controlled trial, where 150 patients with fibromyalgia will be treated with either a careful titration of cannabis oil (5% THC, 5% CBD) or placebo with an allocation ratio of 4:1. Patient reported outcomes, quantitative sensory testing and gut microbiome and metabolome composition will be evaluated at baseline and during treatment. Subjective and objective clinical outcomes will be compared to baseline and end-of-study gut microbiome composition and metabolomic profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult men and women aged 30 years and over.
- •Diagnosis of fibromyalgia confirmed according to the 2016 diagnostic criteria by a pain specialist, with relevant symptoms lasting 12 months or more.
- •An average reported pain ≥ 6 during the preceding week.
- •Eligible for cannabis at the discretion of the treating physician.
- •Has remained symptomatic despite receiving standard care for fibromyalgia including analgesics, anti-depressants (tricyclic and SNRI) and anti-epileptic agents.
排除标准
- •Patients who have used cannabis during the preceding month.
- •Any significant comorbid condition at the discretion of the PI (e.g. inflammatory arthritis, inflammatory bowel disease, cancer).
- •Personal or family history of psychotic disorders.
- •Current or past anxiety disorder.
- •Any uncontrolled psychiatric pathology.
- •Current or history of substance addiction or abuse.
- •Diagnosed dementia or cognitive impairment.
- •Personal history of cardiovascular disease.
- •Pregnancy, lactation or intention to conceive.
- •Known allergy to any of the cannabis oil ingredients.
- •Patients with a history of seizure disorder (excluding childhood febrile convulsions) or epilepsy.
- •Active liver disease.
- •Any contraindication to the use of MC.
- •Inflammatory Bowel Disease (IBD).
研究组 & 干预措施
Active Comparator: Cannabis Oil (5% THC/5% CBD)
Participants in this arm will receive cannabis oil containing a balanced formulation of 5% THC and 5% CBD. The intervention will span three months, including a six-week titration period to optimize dosing, followed by a maintenance phase. Doses will be self-administered sublingually and adjusted based on individual tolerance and efficacy. Comprehensive assessments will monitor clinical outcomes, gut microbiome composition, and circulating metabolomics to explore correlations with treatment response and safety.
This arm will comprise 120 patients.
干预措施: Cannabis Oil (5% THC/5% CBD) (Drug)
Sham Comparator: Placebo Oil
Participants in this arm will receive placebo oil, which is visually and chemically matched to the active cannabis oil but contains no active cannabinoids (THC or CBD). Like the active arm, participants will undergo a three-month intervention, including a six-week titration period and maintenance phase. Outcomes, including clinical measures and biological analyses, will be used as a control to evaluate the therapeutic effects of the cannabis oil.
This arm will comprise 30 patients.
干预措施: Sham Cannabis Oil (Drug)
结局指标
主要结局
correlation of microbiome composition or serum metabolomics with pain reduction
时间窗: Three Months
Any correlation of the gut microbiome composition or serum metabolomics with pain reduction following a 3-months treatment period with cannabis oil.
次要结局
- Change in sleep quality(Three Months)
- Change in quality of life(Three Months)
- Change in anxiety and depression(Three Months)
- Patient global impression of changes(Three Months)
- Pain Intensity(Three Months)
- Changes in gut microbiome and blood metabolites following 3 months treatment with cannabis oil(Three Months)
- correlation of microbiome composition and serum metabolomics with clinical measures(Three Months)
研究者
Amir Minerbi MD
Director
Rambam Health Care Campus